Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Merck
Boehringer Ingelheim
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lucerastat

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Lucerastat?

Lucerastat is an investigational drug.

There have been 6 clinical trials for Lucerastat. The most recent clinical trial was a Phase 1 trial, which was initiated on December 15th 2018.

The most common disease conditions in clinical trials are Fabry Disease and [disabled in preview]. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and [disabled in preview].

There are four US patents protecting this investigational drug and sixty-six international patents.

Recent Clinical Trials for Lucerastat
TitleSponsorPhase
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart FunctionIdorsia Pharmaceuticals Ltd.Phase 1
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseIdorsia Pharmaceuticals Ltd.Phase 3
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseIdorsia Pharmaceuticals Ltd.Phase 3

See all Lucerastat clinical trials

Clinical Trial Summary for Lucerastat

Top disease conditions for Lucerastat
Top clinical trial sponsors for Lucerastat

See all Lucerastat clinical trials

US Patents for Lucerastat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucerastat   Start Trial Method for treatment of CNS-involved lysosomal storage diseases Monsanto Company (St. Louis, MO)   Start Trial
Lucerastat   Start Trial Use of alkylated iminosugars to treat multidrug resistance G.D. Searle & Company (Chicago, IL)   Start Trial
Lucerastat   Start Trial Use of glucosidase inhibitors for therapy of mucovisidosis Centre National de la Recherche Scientifique (C.N.R.S.) (Paris, FR) Universite de Poitiers (Poitiers, FR)   Start Trial
Lucerastat   Start Trial Use of glucosidase inhibitors for therapy of mucovisidosis Centre National de la Recherche Scientifique (C.N.R.S.) (Paris, FR) Universite de Poitiers (Poitiers, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lucerastat

Drugname Country Document Number Estimated Expiration Related US Patent
Lucerastat Austria 148456 2013-05-13   Start Trial
Lucerastat Austria 268598 2013-05-13   Start Trial
Lucerastat Australia 5813898 2013-05-13   Start Trial
Lucerastat Australia 6783294 2013-05-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
Moodys
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.